Silvia Armaroli
University of Siena
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Silvia Armaroli.
Journal of Medicinal Chemistry | 2014
Maurizio Taddei; Serena Ferrini; Luca Giannotti; Massimo Corsi; Fabrizio Manetti; Giuseppe Giannini; Loredana Vesci; Ferdinando Maria Milazzo; Domenico Alloatti; Mario B. Guglielmi; Massimo Castorina; Maria Luisa Cervoni; Marcella Barbarino; Rosanna Foderà; Valeria Carollo; Claudio Pisano; Silvia Armaroli; Walter Cabri
Ruthenium catalyzed 1,3-cycloaddition (click chemistry) of an azido moiety installed on dihydroxycumene scaffold with differently substituted aryl propiolates gave a new family of 1,4,5-trisubstituted triazole carboxylic acid derivatives that showed high affinity toward Hsp90 associated with cell proliferation inhibition, both in nanomolar range. The 1,5 arrangement of the resorcinol, the aryl moieties, and the presence of an alkyl (secondary) amide in position 4 of the triazole ring were essential to get high activity. Docking simulations suggested that the triazoles penetrate the Hsp90 ATP binding site. Some 1,4,5-trisubstituted triazole carboxamides induced dramatic depletion of the examined client proteins and a very strong increase in the expression levels of the chaperone Hsp70. In vitro metabolic stability and in vivo preliminary studies on selected compounds have shown promising results comparable to the potent Hsp90 inhibitor NVP-AUY922. One of them, (compound 18, SST0287CL1) was selected for further investigation as the most promising drug candidate.
Journal of Medicinal Chemistry | 2008
Mauro Gobbini; Silvia Armaroli; Leonardo Banfi; Alessandra Benicchio; Giulio Carzana; Giorgio Fedrizzi; Patrizia Ferrari; Giuseppe Giacalone; Michele Giubileo; Giuseppe Marazzi; Rosella Micheletti; Barbara Moro; Marco Pozzi; Piero Enrico Scotti; Marco Torri; Alberto Cerri
We report the synthesis and biological properties of novel inhibitors of the Na(+),K(+)-ATPase as positive inotropic compounds. Following our previously described model from which Istaroxime was generated, the 5alpha,14alpha-androstane skeleton was used as a scaffold to study the space around the basic chain of our lead compound. Some compounds demonstrated higher potencies than Istaroxime on the receptor and the (E)-3-[(R)-3-pyrrolidinyl]oxime derivative, 15, was the most potent; as further confirmation of our model, the E isomers of the oxime are more potent than the Z form. The compounds tested in the guinea pig model induced positive inotropic effects, which are correlated to the in vitro inhibitory potency on the Na(+),K(+)-ATPase. The finding that all tested compounds resulted less proarrhythmogenic than digoxin, a currently clinically used positive inotropic agent, suggests that this could be a feature of the 3-aminoalkyloxime derivative class of 5alpha,14alpha-androstane.
Bioorganic & Medicinal Chemistry Letters | 2007
Maurizio Botta; Silvia Armaroli; Daniele Castagnolo; Gabriele Fontana; Paula Pera; Ezio Bombardelli
Journal of Medicinal Chemistry | 2001
Giuseppe Campiani; Meri De Angelis; Silvia Armaroli; Caterina Fattorusso; Bruno Catalanotti; Anna Ramunno; Vito Nacci; Ettore Novellino; Christof Grewer; Diana Ionescu; Thomas Rauen; Roger Griffiths; Colin Sinclair; Elena Fumagalli; Tiziana Mennini
Tetrahedron-asymmetry | 2004
Daniele Castagnolo; Silvia Armaroli; Federico Corelli; Maurizio Botta
Archive | 2014
Gianandrea Quattrociocchi; Roberto Castagnani; Silvia Armaroli; Vincenzo Colangeli; Walter Cabri
Archive | 2012
Walter Cabri; Roberto Castagnani; Silvia Armaroli; Gianandrea Quattrociocchi; Vincenzo Colangeli
Archive | 2008
Mauro Marzi; Walter Cabri; Fabrizio Giorgi; Elena Badaloni; Silvia Armaroli; Giuseppe Marazzi
Archive | 2008
Walter Cabri; Mauro Marzi; Fabrizio Giorgi; Elena Badaloni; Silvia Armaroli; Giuseppe Marazzi
Archive | 2006
Alberto Cerri; Silvia Armaroli; Marco Torri